Pneumococcal Awareness Council of Experts (PACE) | |
---|---|
Location | United States |
Key people | Ciro A. de Quadros Orin Levine |
Established | December 2006 |
The Pneumococcal Awareness Council of Experts (PACE) is a project of the Sabin Vaccine Institute and is composed of global experts in infectious diseases and vaccines. [1] Established in December 2006, The Council seeks to raise awareness among policymakers and aims to secure global commitments to prevent pneumococcal disease, a leading infectious killer of children and adults worldwide. [2] The Council works in collaboration and partnership with countries, NGOs, academia and industry.
PACE is made up of 21 global experts on infectious diseases and vaccines from 17 countries around the world. The Council is chaired by Ciro A. de Quadros, Executive Vice President of the Sabin Vaccine Institute and Orin Levine, Executive Director of PneumoADIP [3] at the Johns Hopkins Bloomberg School of Public Health.
PACE has hosted and participated in a number of events worldwide to help raise awareness about pneumococcal disease.
On May 4, 2007, the launch of PACE was announced at a press conference in Washington, D.C. At the event, PACE gave its first annual Global Leadership Award. [10] The Global Leadership Award is given annually by PACE to recognize an individual, organization or country that has championed pneumococcal disease prevention and made a significant contribution towards policies that advance the introduction of pneumococcal conjugate vaccines. PACE Global Leadership Award recipients include: Dr. Thomas Cherian, who has helped accelerate the surveillance of pneumonia throughout the developing world and contributed to research on the global pneumococcal disease burden. The Health Minister of Rwanda – the first country in Africa to introduce pneumococcal conjugate vaccines; and the Health Minister of Costa Rica – the first country in Latin America to implement a nationwide vaccination program. [11]
On November 20, 2007, PACE's European launch took place in Prague, Czech Republic with representatives from professional societies, PACE member Pavla Krizova, and the Czech Ministry of Health in attendance. [11]
On February 15, 2008, PACE held a press event during the 3rd Regional Pneumococcal Symposium [12] in Istanbul, Turkey to call upon policy leaders in Turkey and the region to assure access to pneumococcal vaccines and to support the expansion of health systems to deliver them and monitor their impact. [13]
On June 10, 2008, PACE along with the Sabin Vaccine Institute, PATH and PneumoADIP, participated in the 6th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD-6) [14] in Reykjavík, Iceland. PACE issued a Global Call to Action on Pneumococcal Disease Prevention, [15] urging governments to take steps to make financing available for access to pneumococcal vaccines. [16]
On October 24, 2008, over 100 professional medical societies, institutions and organizations from around the world had signed PACE’s Global Call to Action to urge governments, donors and industry to ensure access to pneumococcal vaccines. Rwanda announced that they would be one of the first two countries to introduce the pneumococcal vaccine into its national immunization program in the spring of 2009. [17]
On January 31, 2009 PACE and the Hib Initiative [18] hosted Childhood Pneumonia and Meningitis: Recent Advances [19] at Aga Khan University in Karachi, Pakistan. The event, brought together stakeholders in child health from Pakistan, including health professionals, representatives from the Ministry of Health and EPI officials. Event leaders, PACE Co-chair Dr. Ciro de Quadros and PACE member Dr. Zulfiqar Bhutta, highlighted the role of advocacy in combating childhood pneumonia and meningitis. [20]
On March 3, 2009, PACE, in conjunction with the Sabin Vaccine Institute, PneumoADIP and the WHO, hosted a media briefing at the Sabin Vaccine Institute's 4th Regional Pneumococcal Symposium [21] in Johannesburg, South Africa, at which PACE released two new studies, Sequelae Due to Bacterial Meningitis among African Children: A Systematic Literature Review, [22] and Bacterial Infections in Persons with Sickle Cell Disease: A Review of Data from Africa with a Focus on Pneumococcal Disease. [23] The event also sought to highlight South Africa's introduction of the pneumococcal vaccine, with support from the GAVI Alliance. [24]
In October 2009, PACE conducted a briefing and one-on-one meetings with members of the European Parliament and European Commission to recommend action on pneumococcal disease.
On November 1–2, 2009 PACE, a member of the World Pneumonia Day Coalition, sponsored a press conference, policymaker roundtable, rally, march and symposium to commemorate World Pneumonia Day in Bangladesh where the country’s leaders and advocates focused their attention on the prevention and treatment of pneumonia. These events and activities were led by PACE member Dr. Samir K. Saha. PACE World Pneumonia Day events also took place in Brazil, Dominican Republic, Kenya, South Africa, the Czech Republic, Israel, Pakistan, China and the Philippines.
In 2008, PACE launched its Global Call to Action on Pneumococcal Disease Prevention [15] in partnership with 114 professional medical societies, organizations and institutions from around the world. [25]
PACE commissioned two studies, Sequelae Due to Bacterial Meningitis among African Children: A Systematic Literature Review, [22] and Bacterial Infections in Persons with Sickle Cell Disease: A Review of Data from Africa with a Focus on Pneumococcal Disease, [23] that highlighted the increased risk for children in Africa of contracting pneumococcal disease and suffering its devastating consequences. It was found that African children who contract pneumococcal disease are 36 times as likely to have sickle-cell disease, a blood disorder prevalent in African children that increases the risk for infectious diseases and early death. [22] Inn addition, the research showed that up to one-half of all children in Africa who get pneumococcal meningitis will either die or be disabled as a consequence of the disease, even when treated with antibiotics in a hospital. As the three leading causes of bacterial meningitis in childhood are vaccine preventable, the regular use of conjugate vaccines would reduce the high burden of morbidity and mortality in both epidemic and endemic settings. [23]
Pneumonia is an inflammatory condition of the lung primarily affecting the small air sacs known as alveoli. Symptoms typically include some combination of productive or dry cough, chest pain, fever, and difficulty breathing. The severity of the condition is variable.
Streptococcus pneumoniae, or pneumococcus, is a Gram-positive, spherical bacteria, alpha-hemolytic member of the genus Streptococcus. They are usually found in pairs (diplococci) and do not form spores and are non motile. As a significant human pathogenic bacterium S. pneumoniae was recognized as a major cause of pneumonia in the late 19th century, and is the subject of many humoral immunity studies.
Pneumococcal polysaccharide vaccine (PPSV)—known as Pneumovax 23 (PPV-23)—is the first pneumococcal vaccine derived from a capsular polysaccharide.
Meningococcal disease describes infections caused by the bacterium Neisseria meningitidis. It has a high mortality rate if untreated but is vaccine-preventable. While best known as a cause of meningitis, it can also result in sepsis, which is an even more damaging and dangerous condition. Meningitis and meningococcemia are major causes of illness, death, and disability in both developed and under-developed countries.
Pneumococcal conjugate vaccine is a pneumococcal vaccine and a conjugate vaccine used to protect infants, young children, and adults against disease caused by the bacterium Streptococcus pneumoniae (pneumococcus). It contains purified capsular polysaccharide of pneumococcal serotypes conjugated to a carrier protein to improve antibody response compared to the pneumococcal polysaccharide vaccine. The World Health Organization (WHO) recommends the use of the conjugate vaccine in routine immunizations given to children.
Pneumococcal vaccines are vaccines against the bacterium Streptococcus pneumoniae. Their use can prevent some cases of pneumonia, meningitis, and sepsis. There are two types of pneumococcal vaccines: conjugate vaccines and polysaccharide vaccines. They are given by injection either into a muscle or just under the skin.
A pneumococcal infection is an infection caused by the bacterium Streptococcus pneumoniae, which is also called the pneumococcus. S. pneumoniae is a common member of the bacterial flora colonizing the nose and throat of 5–10% of healthy adults and 20–40% of healthy children. However, it is also a cause of significant disease, being a leading cause of pneumonia, bacterial meningitis, and sepsis. The World Health Organization estimates that in 2005 pneumococcal infections were responsible for the death of 1.6 million children worldwide.
Meningitis is acute or chronic inflammation of the protective membranes covering the brain and spinal cord, collectively called the meninges. The most common symptoms are fever, headache, and neck stiffness. Other symptoms include confusion or altered consciousness, nausea, vomiting, and an inability to tolerate light or loud noises. Young children often exhibit only nonspecific symptoms, such as irritability, drowsiness, or poor feeding. A non-blanching rash may also be present.
Maria Deloria Knoll is an expert in the fields of epidemiology, disease surveillance, vaccine trial conduct, and bio-statistics. She currently serves as associate director of Science at the International Vaccine Access Center (IVAC), an organization dedicated to accelerating global access to life-saving vaccines, at the Johns Hopkins Bloomberg School of Public Health in Baltimore, Maryland.
Lois Privor-Dumm is an expert in the field of vaccine introduction. She is especially recognized for her work with new vaccine introduction, which has included strategies to accelerate access in low and middle-income countries, policy research, advocacy, communications and large country introduction.
Orin Levine is an epidemiologist known for his work in the fields of international public health, child survival, and pneumonia. He is currently the director of vaccine delivery at the Bill & Melinda Gates Foundation in Seattle, US. In the past he was the executive director of the International Vaccine Access Center (IVAC), the co-chair of the Pneumococcal Awareness Council of Experts (PACE), and is a professor at The Johns Hopkins Bloomberg School of Public Health in the Department of International Health. He is also an adjunct assistant professor of epidemiology at The Rollins School of Public Health at Emory University in Atlanta. Additionally, he is currently president of the American Society of Tropical Medicine and Hygiene (ASTMH) Council on Global Health. He resides in Washington, D.C.
World Pneumonia Day provides an annual forum for the world in the fight against pneumonia. More than 100 organizations representing the interests of children joined forces as the Global Coalition against Child Pneumonia to hold the first World Pneumonia Day on 12 November 2009. Save The Children artist ambassadors Gwyneth Paltrow and Hugh Laurie, Charles MacCormack of Save The Children, Orin Levine of PneumoADIP, Lance Laifer of Hedge Funds vs. Malaria & Pneumonia, the Global Health Council, the GAVI Alliance, and the Sabin Vaccine Institute joined together in a call to action asking people to participate in World Pneumonia Day on 2 November.
Katherine "Kate" L. O'Brien is a Canadian American pediatric infectious disease physician, epidemiologist, and vaccinologist who specializes in the areas of pneumococcal epidemiology, pneumococcal vaccine trials and impact studies, and surveillance for pneumococcal disease. She is also known as an expert in infectious diseases in American Indian populations. O’Brien is currently the Director of the World Health Organization's Department of Immunization, Vaccines and Biologicals.
The African meningitis belt is a region in sub-Saharan Africa where the rate of incidence of meningitis is very high. It extends from Senegal to Ethiopia, and the primary cause of meningitis in the belt is Neisseria meningitidis.
The Global Coalition Against Child Pneumonia exists to raise global awareness about the deadly toll of the number 1 killer of children - pneumonia. Every year 155 million children under 5 get sick and 1.6 million lose their lives to pneumonia, more than all child deaths combined from AIDS, malaria and measles. Almost all of these child deaths occur in developing countries with most concentrated in just seven - India, China, Democratic Republic of Congo, Ethiopia, Nigeria, Pakistan and Afghanistan.
Universal Immunisation Programme (UIP) is a vaccination programme launched by the Government of India in 1985. It became a part of Child Survival and Safe Motherhood Programme in 1992 and is currently one of the key areas under the National Health Mission since 2005. The programme now consists of vaccination for 12 diseases- tuberculosis, diphtheria, pertussis, tetanus, poliomyelitis, measles, hepatitis B, rotaviral gastroenteritis, Japanese encephalitis, rubella, pneumonia and Pneumococcal diseases. Hepatitis B and Pneumococcal diseases were added to the UIP in 2007 and 2017 respectively. The cost of all the vaccines are borne entirely by the Government of India and is funded through taxes with a budget of ₹7,234 crore (US$910 million) in 2022 and the program covers all residents of India, including foreign residents.
GAVI, officially Gavi, the Vaccine Alliance is a public–private global health partnership with the goal of increasing access to immunization in poor countries. In 2016, Gavi channeled more than half of total donor assistance for health, and most donor assistance for immunization, by monetary measure.
George Rainer Siber is a medical researcher and vaccine expert with 48 years of experience in developing numerous vaccines, therapeutic antibodies, and diagnostic agents for infectious diseases.
Claire Veronica Broome is an American epidemiologist, specializing in public health surveillance and vaccine evaluation, who has contributed to the development and effective utilization of key vaccines against pathogens causing pneumonia and meningitis.
Samir Kumar Saha is an eminent Bangladeshi microbiologist and public health expert. He is the professor, senior consultant and head of the department of Diagnostic Division of Microbiology at the Dhaka Shishu Hospital for children and also the executive director of The Child Health Research Foundation (CHRF) at the Bangladesh Institute of Child Health.